This doesn't address the main point of failing to meet the primary endpoint - I think the most significant issue.
Secondly, the proposed mechanistic link is much more obscure.
1) MSCs reduce LV inflammation - theoretical mechanism, uncertain how or if they do this, or for how long, as MSCs are a transient cell population
2) How decreased inflammation increases "contractility and forward flow"
3) And how the above reduces heart attacks, stroke and death
Very much a mechanism that doesn't make sense. Again, I sound like a broken record, but the expert cardiology panel said the exact same thing when the results were released.
Maybe you know more than them. You sure know how to copy and paste an argument, that's for sure!
Cell Therapy News/Articles, page-17139
-
- There are more pages in this discussion • 762 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |